{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:36:05Z","timestamp":1761896165489},"reference-count":74,"publisher":"Impact Journals, LLC","issue":"23","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2015,8,14]]},"DOI":"10.18632\/oncotarget.4415","type":"journal-article","created":{"date-parts":[[2015,9,15]],"date-time":"2015-09-15T04:50:54Z","timestamp":1442292654000},"page":"19807-19818","source":"Crossref","is-referenced-by-count":26,"title":["miR-181b as a therapeutic agent for chronic lymphocytic leukemia in the E\u03bc-TCL1 mouse model"],"prefix":"10.18632","volume":"6","author":[{"given":"Antonella","family":"Bresin","sequence":"first","affiliation":[{"name":"Universit\u00e0 di Ferrara, Dipartimento di Morfologia, Chirurgia e Medicina Sperimentale, Ferrara, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Callegari","sequence":"additional","affiliation":[{"name":"Universit\u00e0 di Ferrara, Dipartimento di Morfologia, Chirurgia e Medicina Sperimentale, Ferrara, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucilla","family":"D\u2019Abundo","sequence":"additional","affiliation":[{"name":"Universit\u00e0 di Ferrara, Dipartimento di Morfologia, Chirurgia e Medicina Sperimentale, Ferrara, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caterina","family":"Cattani","sequence":"additional","affiliation":[{"name":"Istituto Dermopatico dell'Immacolata, IDI-IRCCS, Laboratorio di Oncologia Molecolare, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristian","family":"Bassi","sequence":"additional","affiliation":[{"name":"Universit\u00e0 di Ferrara, Dipartimento di Morfologia, Chirurgia e Medicina Sperimentale, Ferrara, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Zagatti","sequence":"additional","affiliation":[{"name":"Universit\u00e0 di Ferrara, Dipartimento di Morfologia, Chirurgia e Medicina Sperimentale, Ferrara, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Grazia","family":"Narducci","sequence":"additional","affiliation":[{"name":"Istituto Dermopatico dell'Immacolata, IDI-IRCCS, Laboratorio di Oncologia Molecolare, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabetta","family":"Caprini","sequence":"additional","affiliation":[{"name":"Istituto Dermopatico dell'Immacolata, IDI-IRCCS, Laboratorio di Oncologia Molecolare, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuri","family":"Pekarsky","sequence":"additional","affiliation":[{"name":"Human Cancer Genetics Program and Department of Molecular Virology, Immunology and Medical Genetics, OSU School of Medicine, Ohio State University, Columbus, OH, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo M.","family":"Croce","sequence":"additional","affiliation":[{"name":"Human Cancer Genetics Program and Department of Molecular Virology, Immunology and Medical Genetics, OSU School of Medicine, Ohio State University, Columbus, OH, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Sabbioni","sequence":"additional","affiliation":[{"name":"Universit\u00e0 di Ferrara, Dipartimento di Scienze della Vita e Biotecnologie, Ferrara, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giandomenico","family":"Russo","sequence":"additional","affiliation":[{"name":"Istituto Dermopatico dell'Immacolata, IDI-IRCCS, Laboratorio di Oncologia Molecolare, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Negrini","sequence":"additional","affiliation":[{"name":"Universit\u00e0 di Ferrara, Dipartimento di Morfologia, Chirurgia e Medicina Sperimentale, Ferrara, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2015,6,10]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1056\/NEJMra041720","article-title":"Chronic lymphocytic leukemia","volume":"352","author":"Ferrarini","year":"2005","journal-title":"The New England journal of medicine"},{"key":"2","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.V46.2.219.219","article-title":"Clinical staging of chronic lymphocytic leukemia","volume":"46","author":"Pasternack","year":"1975","journal-title":"Blood"},{"key":"3","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1056\/NEJMoa023143","article-title":"ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia","volume":"348","author":"Montserrat","year":"2003","journal-title":"The New England journal of medicine"},{"key":"4","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1182\/blood.V100.4.1177.h81602001177_1177_1184","article-title":"Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors","volume":"100","author":"Copplestone","year":"2002","journal-title":"Blood"},{"key":"5","doi-asserted-by":"crossref","first-page":"4944","DOI":"10.1182\/blood-2002-10-3306","article-title":"ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile","volume":"101","author":"Davis","year":"2003","journal-title":"Blood"},{"key":"6","doi-asserted-by":"crossref","first-page":"12530","DOI":"10.1073\/pnas.91.26.12530","article-title":"Identification of the TCL1 gene involved in T-cell malignancies","volume":"91","author":"Russo","year":"1994","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"7","first-page":"2095","article-title":"Regulation of TCL1 expression in B- and T-cell lymphomas and reactive lymphoid tissues","volume":"60","author":"Croce","year":"2000","journal-title":"Cancer research"},{"key":"8","doi-asserted-by":"crossref","first-page":"9809","DOI":"10.1073\/pnas.96.17.9809","article-title":"TCL1 oncogene expression in AIDS-related lymphomas and lymphoid tissues","volume":"96","author":"Wall","year":"1999","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"9","doi-asserted-by":"crossref","first-page":"5007","DOI":"10.1182\/blood-2002-10-3297","article-title":"TCL1 expression in plasmacytoid dendritic cells (DC2s) and the related CD4+ CD56+ blastic tumors of skin","volume":"101","author":"Jones","year":"2003","journal-title":"Blood"},{"key":"10","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/j.1365-2559.2006.02506.x","article-title":"Expression of TCL1 and CD27 in primary cutaneous B-cell lymphomas","volume":"49","author":"Baroni","year":"2006","journal-title":"Histopathology"},{"key":"11","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/sj.leu.2404017","article-title":"TCL1 shows a regulated expression pattern in chronic lymphocytic leukemia that correlates with molecular subtypes and proliferative state","volume":"20","author":"Jones","year":"2006","journal-title":"Leukemia"},{"key":"12","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.it.2013.07.002","article-title":"B cell receptor signaling in chronic lymphocytic leukemia","volume":"34","author":"Chiorazzi","year":"2013","journal-title":"Trends in immunology"},{"key":"13","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1182\/blood.V120.21.SCI-27.SCI-27","article-title":"The B-cell receptor signaling pathway as a therapeutic target in CLL","volume":"120","author":"Byrd","year":"2012","journal-title":"Blood"},{"key":"14","doi-asserted-by":"crossref","first-page":"4313","DOI":"10.1182\/blood-2011-06-338855","article-title":"B-cell receptor signaling in chronic lymphocytic leukemia","volume":"118","author":"Packham","year":"2011","journal-title":"Blood"},{"key":"15","doi-asserted-by":"crossref","first-page":"4497","DOI":"10.1200\/JCO.2007.15.4393","article-title":"Novel insights in chronic lymphocytic leukemia: are we getting closer to understanding the pathogenesis of the disease?","volume":"26","author":"Ghia","year":"2008","journal-title":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology"},{"key":"16","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1182\/blood.V98.10.3050","article-title":"Survival of leukemic B cells promoted by engagement of the antigen receptor","volume":"98","author":"Schattner","year":"2001","journal-title":"Blood"},{"key":"17","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1182\/blood.V99.8.2969","article-title":"Involvement of protein kinase C and phosphatidylinositol 3-kinase pathways in the survival of B-cell chronic lymphocytic leukemia cells","volume":"99","author":"Gil","year":"2002","journal-title":"Blood"},{"key":"18","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1182\/blood-2002-02-0539","article-title":"Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: association with protein kinase Cdelta","volume":"100","author":"Decker","year":"2002","journal-title":"Blood"},{"key":"19","doi-asserted-by":"crossref","first-page":"4820","DOI":"10.1182\/blood-2004-07-2669","article-title":"Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B cells","volume":"105","author":"Efremov","year":"2005","journal-title":"Blood"},{"key":"20","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1200\/JCO.1999.17.1.399","article-title":"B-cell chronic lymphocytic leukemia: a bird of a different feather","volume":"17","author":"Hamblin","year":"1999","journal-title":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology"},{"key":"21","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1182\/blood.V82.6.1820.1820","article-title":"bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia","volume":"82","author":"Reed","year":"1993","journal-title":"Blood"},{"key":"22","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1182\/blood.V98.3.814","article-title":"p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation","volume":"98","author":"Stankovic","year":"2001","journal-title":"Blood"},{"key":"23","doi-asserted-by":"crossref","first-page":"4382","DOI":"10.1182\/blood.V87.10.4382.bloodjournal87104382","article-title":"Interleukin-8 induces the accumulation of B-cell chronic lymphocytic leukemia cells by prolonging survival in an autocrine fashion","volume":"87","author":"Foa","year":"1996","journal-title":"Blood"},{"key":"24","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1080\/10428190412331272703","article-title":"Microenvironmental interactions and survival of CLL B-cells","volume":"45","author":"Reed","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"25","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Wierda","year":"2013","journal-title":"The New England journal of medicine"},{"key":"26","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","article-title":"Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies","volume":"31","author":"Chang","year":"2013","journal-title":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology"},{"key":"27","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1586\/14737140.2015.990442","article-title":"Progress in the treatment of elderly\/unfit chronic lymphocytic leukemia patients: results of the German CLL-11 trial","volume":"15","author":"Molica","year":"2015","journal-title":"Expert review of anticancer therapy"},{"key":"28","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","article-title":"Idelalisib and rituximab in relapsed chronic lymphocytic leukemia","volume":"370","author":"Flinn","year":"2014","journal-title":"The New England journal of medicine"},{"key":"29","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1182\/blood-2014-05-577122","article-title":"Mouse models in the study of chronic lymphocytic leukemia pathogenesis and therapy","volume":"124","author":"Klein","year":"2014","journal-title":"Blood"},{"key":"30","doi-asserted-by":"crossref","first-page":"6955","DOI":"10.1073\/pnas.102181599","article-title":"Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression","volume":"99","author":"Croce","year":"2002","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"31","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1038\/leu.2010.46","article-title":"CD5+CD23+ leukemic cell populations in TCL1 transgenic mice show significantly increased proliferation and Akt phosphorylation","volume":"24","author":"Pekarsky","year":"2010","journal-title":"Leukemia"},{"key":"32","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1182\/blood-2005-12-011213","article-title":"Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia","volume":"108","author":"Byrd","year":"2006","journal-title":"Blood"},{"key":"33","doi-asserted-by":"crossref","first-page":"11713","DOI":"10.1073\/pnas.0604564103","article-title":"B cell receptors in TCL1 transgenic mice resemble those of aggressive, treatment-resistant human chronic lymphocytic leukemia","volume":"103","author":"Chiorazzi","year":"2006","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"34","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0092-8674(04)00045-5","article-title":"MicroRNAs: genomics, biogenesis, mechanism, and function","volume":"116","author":"Bartel","year":"2004","journal-title":"Cell"},{"key":"35","first-page":"54","article-title":"miRNA dysregulation in cancer: towards a mechanistic understanding","volume":"5","author":"Rao","year":"2014","journal-title":"Frontiers in genetics"},{"key":"36","doi-asserted-by":"crossref","first-page":"15524","DOI":"10.1073\/pnas.242606799","article-title":"Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia","volume":"99","author":"Rai","year":"2002","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"37","doi-asserted-by":"crossref","first-page":"11755","DOI":"10.1073\/pnas.0404432101","article-title":"MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias","volume":"101","author":"Dono","year":"2004","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"38","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1056\/NEJMoa050995","article-title":"A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia","volume":"353","author":"Fabbri","year":"2005","journal-title":"The New England journal of medicine"},{"key":"39","doi-asserted-by":"crossref","first-page":"3872","DOI":"10.1182\/blood-2009-06-229211","article-title":"Karyotype-specific microRNA signature in chronic lymphocytic leukemia","volume":"114","author":"Balatti","year":"2009","journal-title":"Blood"},{"key":"40","doi-asserted-by":"crossref","first-page":"4141","DOI":"10.1158\/1078-0432.CCR-13-2497","article-title":"microRNAome expression in chronic lymphocytic leukemia: comparison with normal B-cell subsets and correlations with prognostic and clinical parameters","volume":"20","author":"Matis","year":"2014","journal-title":"Clin Cancer Res"},{"key":"41","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.beha.2007.02.003","article-title":"The role of microRNA and other non-coding RNA in the pathogenesis of chronic lymphocytic leukemia","volume":"20","author":"Croce","year":"2007","journal-title":"Best Pract Res Clin Haematol"},{"key":"42","doi-asserted-by":"crossref","first-page":"200","DOI":"10.4161\/cbt.8.3.7333","article-title":"microRNAs and their potential target genes in leukemia pathogenesis","volume":"8","author":"Ji","year":"2009","journal-title":"Cancer Biol Ther"},{"key":"43","doi-asserted-by":"crossref","first-page":"13944","DOI":"10.1073\/pnas.0506654102","article-title":"miR-15 and miR-16 induce apoptosis by targeting BCL2","volume":"102","author":"Dono","year":"2005","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"44","doi-asserted-by":"crossref","first-page":"5166","DOI":"10.1073\/pnas.0800121105","article-title":"MiR-15a and miR-16-1 cluster functions in human leukemia","volume":"105","author":"Aqeilan","year":"2008","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"45","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.cub.2007.06.068","article-title":"p53-mediated activation of miRNA34 candidate tumor-suppressor genes","volume":"17","author":"Moore","year":"2007","journal-title":"Curr Biol"},{"key":"46","doi-asserted-by":"crossref","first-page":"11590","DOI":"10.1158\/0008-5472.CAN-06-3613","article-title":"Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181","volume":"66","author":"Rassenti","year":"2006","journal-title":"Cancer research"},{"key":"47","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1124\/mol.110.066258","article-title":"Lyn kinase-dependent regulation of miR181 and myeloid cell leukemia-1 expression: implications for drug resistance in myelogenous leukemia","volume":"78","author":"Graves","year":"2010","journal-title":"Mol Pharmacol"},{"key":"48","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.mito.2011.09.001","article-title":"miR-181 targets multiple Bcl-2 family members and influences apoptosis and mitochondrial function in astrocytes","volume":"12","author":"Giffard","year":"2012","journal-title":"Mitochondrion"},{"key":"49","doi-asserted-by":"crossref","first-page":"11111","DOI":"10.1158\/0008-5472.CAN-07-2858","article-title":"MicroRNAs as potential agents to alter resistance to cytotoxic anticancer therapy","volume":"67","author":"Slack","year":"2007","journal-title":"Cancer research"},{"key":"50","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.cancergencyto.2010.09.007","article-title":"MicroRNA in chronic lymphocytic leukemia: transitioning from laboratory-based investigation to clinical application","volume":"203","author":"Croce","year":"2010","journal-title":"Cancer Genet Cytogenet"},{"key":"51","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1038\/aps.2013.35","article-title":"Friend or foe: the role of microRNA in chemotherapy resistance","volume":"34","author":"Yang","year":"2013","journal-title":"Acta Pharmacol Sin"},{"key":"52","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.1182\/blood-2011-01-333484","article-title":"miR-181b is a biomarker of disease progression in chronic lymphocytic leukemia","volume":"118","author":"Croce","year":"2011","journal-title":"Blood"},{"key":"53","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1111\/j.1349-7006.1998.tb03275.x","article-title":"Expression of the TCL1 gene at 14q32 in B-cell malignancies but not in adult T-cell leukemia","volume":"89","author":"Seto","year":"1998","journal-title":"Jpn J Cancer Res"},{"key":"54","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/0145-2126(90)90167-8","article-title":"Establishment of a karyotypically normal B-chronic lymphocytic leukemia cell line; evidence of leukemic origin by immunoglobulin gene rearrangement","volume":"14","author":"Guy","year":"1990","journal-title":"Leuk Res"},{"key":"55","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1073\/pnas.97.7.3028","article-title":"Tcl1 enhances Akt kinase activity and mediates its nuclear translocation","volume":"97","author":"Croce","year":"2000","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"56","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0092-8674(00)80405-5","article-title":"Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery","volume":"91","author":"Greenberg","year":"1997","journal-title":"Cell"},{"key":"57","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1126\/science.282.5392.1318","article-title":"Regulation of cell death protease caspase-9 by phosphorylation","volume":"282","author":"Reed","year":"1998","journal-title":"Science"},{"key":"58","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1182\/blood-2007-05-089037","article-title":"The Akt\/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells","volume":"111","author":"Efremov","year":"2008","journal-title":"Blood"},{"key":"59","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/43474","article-title":"NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling","volume":"401","author":"Makarov","year":"1999","journal-title":"Nature"},{"key":"60","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1158\/0008-5472.CAN-05-3426","article-title":"Effect of rapamycin on mouse chronic lymphocytic leukemia and the development of nonhematopoietic malignancies in Emu-TCL1 transgenic mice","volume":"66","author":"Volinia","year":"2006","journal-title":"Cancer research"},{"key":"61","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/sj.gt.3302425","article-title":"RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA","volume":"12","author":"Aigner","year":"2005","journal-title":"Gene therapy"},{"key":"62","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1007\/s11095-008-9693-1","article-title":"Systemic delivery of DNA or siRNA mediated by linear polyethylenimine (L-PEI) does not induce an inflammatory response","volume":"25","author":"Bolcato-Bellemin","year":"2008","journal-title":"Pharmaceutical research"},{"key":"63","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1093\/carcin\/bgs179","article-title":"miR-181a\/b significantly enhances drug sensitivity in chronic lymphocytic leukemia cells via targeting multiple anti-apoptosis genes","volume":"33","author":"Liu","year":"2012","journal-title":"Carcinogenesis"},{"key":"64","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1002\/ijc.25260","article-title":"miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines","volume":"127","author":"Liu","year":"2010","journal-title":"Int J Cancer"},{"key":"65","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/leu.2008.26","article-title":"Contributions of the Raf\/MEK\/ERK, PI3K\/PTEN\/Akt\/mTOR and Jak\/STAT pathways to leukemia","volume":"22","author":"Tafuri","year":"2008","journal-title":"Leukemia"},{"key":"66","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.4161\/cc.9.9.11483","article-title":"The Raf\/MEK\/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy","volume":"9","author":"Libra","year":"2010","journal-title":"Cell Cycle"},{"key":"67","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.advenzreg.2006.01.004","article-title":"Roles of the RAF\/MEK\/ERK and PI3K\/PTEN\/AKT pathways in malignant transformation and drug resistance","volume":"46","author":"D'Assoro","year":"2006","journal-title":"Adv Enzyme Regul"},{"key":"68","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/sj.leu.2403241","article-title":"JAK\/STAT, Raf\/MEK\/ERK, PI3K\/Akt and BCR-ABL in cell cycle progression and leukemogenesis","volume":"18","author":"McCubrey","year":"2004","journal-title":"Leukemia"},{"key":"69","doi-asserted-by":"crossref","first-page":"34833","DOI":"10.1074\/jbc.M605483200","article-title":"A splice variant of CD99 increases motility and MMP-9 expression of human breast cancer cells through the AKT-, ERK-, and JNK-dependent AP-1 activation signaling pathways","volume":"281","author":"Lee","year":"2006","journal-title":"J Biol Chem"},{"key":"70","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.3892\/ijo_00000306","article-title":"Cross-talk between PI3K\/Akt and MEK\/ERK pathways mediates endoplasmic reticulum stress-induced cell cycle progression and cell death in human hepatocellular carcinoma cells","volume":"34","author":"Li","year":"2009","journal-title":"Int J Oncol"},{"key":"71","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1002\/cam4.226","article-title":"Modern treatment in chronic lymphocytic leukemia: impact on survival and efficacy in high-risk subgroups","volume":"3","author":"Rigolin","year":"2014","journal-title":"Cancer Med"},{"key":"72","doi-asserted-by":"crossref","first-page":"4221","DOI":"10.1002\/smll.201301417","article-title":"Antibody conjugated PLGA nanoparticles for targeted delivery of paclitaxel palmitate: efficacy and biofate in a lung cancer mouse model","volume":"9","author":"Benita","year":"2013","journal-title":"Small"},{"key":"73","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1182\/blood-2012-01-407742","article-title":"Targeted nanoparticle delivery overcomes off-target immunostimulatory effects of oligonucleotides and improves therapeutic efficacy in chronic lymphocytic leukemia","volume":"121","author":"Chan","year":"2013","journal-title":"Blood"},{"key":"74","doi-asserted-by":"crossref","first-page":"6185","DOI":"10.1016\/j.biomaterials.2013.04.063","article-title":"Targeted drug delivery and cross-linking induced apoptosis with anti-CD37 based dual-ligand immunoliposomes in B chronic lymphocytic leukemia cells","volume":"34","author":"Byrd","year":"2013","journal-title":"Biomaterials"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.4415","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T15:32:37Z","timestamp":1594827157000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.4415"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,10]]},"references-count":74,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2015,8,14]]}},"alternative-id":["4415","26090867"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.4415","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,10]]}}}